StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
Aggregate of 12 sell-side ratings as of 2026-05-01. Stonvex does not endorse these ratings.
Next report date, year-over-year trend, and recent quarter history.
These are published opinions from external sell-side analysts — not Stonvex recommendations. Ratings may change without notice, may conflict with each other, and may be wrong. Not investment advice.
Consensus aggregated from publicly disclosed sell-side analyst ratings. Stonvex is not a registered investment advisor and does not endorse any of the ratings shown. Past analyst ratings do not predict future price movements.
Earnings (▲ beat / ▼ miss) and ex-dividend dates plotted on the price line. Educational — proximity does not establish causation.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-15 | $5.01 | $4.70 | -6.19% | 0.2M |
| 05-18 | $4.68 | $4.25 | -9.19% | 0.3M |
| 05-19 | $4.18 | $4.07 | -2.63% | 0.2M |
| 05-20 | $4.05 | $4.22 | +4.20% | 0.2M |
| 05-21 | $4.18 | $4.29 | +2.51% | 0.1M |
5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.
Each factor shows WHWK's percentile within the scored universe — observational ranking, not a recommendation.
Past 1 reported quarters: EPS surprise vs estimate and the day-after-release stock reaction. Past performance does not predict future moves.
Sources: Finnhub earnings calendar + Polygon daily aggregates. Reaction direction can diverge from EPS surprise (guidance, macro, or sector flow can dominate the next-day print).
Whitehawk Therapeutics Inc is an oncology therapeutics company applying technologies to tumor biology to develop cancer treatments. Its portfolio includes three antibody-drug conjugate (ADC) candidates designed to address limitations of earlier therapies for patients with difficult-to-treat cancers. The company generates revenue from the sale of its products.
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Q3 2026 (Est.) Expected 2026-08-05 | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|---|
Revenue | $0.00 | $0.00 | $7.14M | $7.14M | $7.14M |
Operating Income | Not available | $-23.52M | $-114.40M | $-89.51M | $-69.97M |
Net Income | Not available | $-22.19M | $-20.60M | $2.65M | $-52.62M |
EPS (Diluted) | $-0.35 | $-0.32 | $-0.33 | $0.04 | $0.37 |
Total Assets | Not available | $127.23M | $150.83M | $167.02M | $180.82M |
Total Liabilities | Not available | $11.06M | $14.52M | $9.85M | $8.76M |
Cash & Equivalents | Not available | $34.79M | $37.57M | $37.93M | $144.94M |
Free Cash Flow OCF − CapEx | Not available | $-22.21M | $-97.98M | $-80.75M | $-65.37M |
Shares Outstanding | Not available | 47.20M | 47.15M | 47.13M | 47.13M |
WHWK is in the extended universe. We surface dollar-volume + price-change percentiles for every US-listed name, but the full 6-factor DNA breakdown (momentum, news, sentiment, flow, relative strength) is only computed on the curated 1137-name primary list.
DNA analysis is not available for this ticker.
Indicator values from Polygon. Educational only — single- indicator triggers in isolation are not a complete trading signal.
Latest Form 13F-HR disclosures from the curated Super Investors list. Click through to see each manager's full long book.